![Steven Boyd](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Boyd
Directeur Général chez
Armistice Capital LLC
Profil
Mr. Steven J.
Boyd is a Founder & Chief Investment Officer at Armistice Capital LLC.
Prior to Armistice, he was a Senior Research Analyst at Senator Investment Group since pre-launch (February 2008).
Before Senator, he was an Associate at York Capital, focusing primarily on investments in consumer and health care equities.
Prior to York, he worked as an Analyst at SAB Capital Management, a value-oriented long/short equity hedge fund.
He began his career as an Analyst at McKinsey & Company.
He received a B.S.
in Economics (with a concentration in Finance) as well as a B.A. in Political Science from The Wharton School of the University of Pennsylvania.
Postes actifs de Steven Boyd
| Sociétés | Poste | Début |
|---|---|---|
Armistice Capital LLC
 Armistice Capital LLC Investment ManagersFinance Armistice seeks to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing primarily in equity securities, equity-related instruments, debt investments, and other assets. The firm typically employs a bottom-up analysis, assessing all components of the company’s capital structure. | Directeur Général | 01/05/2012 |
Anciens postes connus de Steven Boyd
| Sociétés | Poste | Fin |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Président | 08/08/2022 |
| TENAX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 10/06/2022 |
| AYTU BIOPHARMA, INC. | Directeur/Membre du Conseil | 30/08/2021 |
| KIORA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 03/08/2021 |
| VAXART, INC. | Directeur/Membre du Conseil | 28/01/2021 |
Formation de Steven Boyd
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
50
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Tenax Therapeutics, Inc.
 Tenax Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes pharmaceutical therapeutic products | Health Technology |
York Capital Management Global Advisors LLC
 York Capital Management Global Advisors LLC Investment ManagersFinance York is a global, event-driven investment firm which specializes in M&A transactions, distressed situations, restructuring opportunities and special situations including spin-offs and split-ups, litigation opportunities, shareholder agitation and proxy contests, balance sheet arbitrage and consolidations. The firm seeks to generate consistent superior investment results relatively independent of the returns generated by the overall equity markets. Their approach is opportunistic and builds portfolios from the bottom-up on a trade-by-trade basis in response to market conditions. | Finance |
SAB Capital Management
 SAB Capital Management Investment ManagersFinance Provides investment advice | Finance |
Kiora Pharmaceuticals, Inc.
 Kiora Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for the treatment of ophthalmic diseases | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Senator Investment Group LP
 Senator Investment Group LP Investment ManagersFinance Senator pursues a global and opportunistic strategy for investing in distressed debt, value equities and event equities. They also pursue a global and opportunistic strategy for investing in “less-than-liquid” situations, including private or illiquid debt and equity investments. The firm emphasizes capital preservation and seeks to mitigate risk. Their allocation of capital depends upon where it believes the most attractive risk-adjusted opportunities exist. | Finance |
Avalo Therapeutics, Inc.
 Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Armistice Capital LLC
Armistice Capital LLC Investment ManagersFinance Armistice seeks to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing primarily in equity securities, equity-related instruments, debt investments, and other assets. The firm typically employs a bottom-up analysis, assessing all components of the company’s capital structure. | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aytu Biopharma, Inc.
 Aytu Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Vaxart, Inc.
 Vaxart, Inc. BiotechnologyHealth Technology Develops vaccines | Health Technology |
